Aktis Oncology (AKTS) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aktis Oncology is the larger company by market cap ($901.1 million vs $816.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | PHAR |
|---|---|---|
| Share price | $16.15 | $11.54 |
| Market cap | $901.14M | $816.78M |
| 1-day change | -1.52% | -5.10% |
| YTD return | — | -34.69% |
| 1-year return | — | -29.03% |
| 5-year return | — | +39.04% |
| P/E ratio (TTM) | — | 36.06 |
| Forward P/E | — | 64.11 |
| EPS (TTM) | $-1.80 | $0.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $376.13M |
| Revenue growth (YoY) | — | +26.56% |
| Net income (latest FY) | — | $2.85M |
| Gross margin | — | 87.90% |
| Operating margin | — | 6.87% |
| Net margin | — | 0.76% |
| 52-week high | $34.19 | $21.34 |
| 52-week low | $13.96 | $9.11 |
| Distance from 52-week high | -52.76% | -45.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +122.17% | +209.36% |
| Average volume | 408.46K | 21.33K |
| Shares outstanding | 53.93M | 70.78M |
| Employees | 79 | 407 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
AKTS vs PHAR FAQ
Which is bigger, Aktis Oncology or Pharming Group N.V.?
Aktis Oncology (AKTS) is larger, with a market capitalization of $901.14M compared with $816.78M for Pharming Group N.V. (PHAR).
Are Aktis Oncology and Pharming Group N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.